Cognition Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development of a pipeline of disease-modifying small molecule drug candidates that normalize the impaired protein trafficking pathways that are the root cause of many CNS disorders. By so doing, Cognition’s drug candidates aim to preserve brain health and function.
Cognition’s lead candidate, Elayta™ (CT1812), is a proprietary first-in-class, orally dosed and highly brain penetrant small molecule. Elayta was designed to normalize the protein trafficking pathways responsible for synaptic plasticity, which are compromised when the oligomeric form of the Aβ protein binds to neurons. This binding triggers a neurotoxic cascade that disrupts normal protein trafficking and leads to further damaging downstream effects. Elayta displaces oligomers from their target receptor, removing them from brain cell synapses and clearing them out of the brain into the cerebrospinal fluid (CSF).
History
Cognition Therapeutics was founded on a unique combination of biological expertise in synaptic function and plasticity, a deep understanding of and focus on the role of toxic soluble proteins, and proprietary CNS-biased chemistry. With the initial support of the Pittsburgh Life Sciences Greenhouse, dedicated investors and the National Institute on Aging of the NIH, Cognition’s co-founder, Susan Catalano, Ph.D. and her team developed an unbiased high-content screening platform that lead to the identification of Elayta. Elayta is a currently being developed for patients with mild-to-moderate Alzheimer’s disease and has the potential to provide meaningful improvement for patients and their families devastated by this disease.
Mission
Cognition’s mission is to stop the unrelenting progression and impact of neurodegenerative disorders caused by the dysregulation of membrane trafficking pathways, such as Alzheimer’s disease, Parkinson’s disease and ALS.
Elayta’s Status
Based on its initial clinical trial in individuals with mild-to-moderate Alzheimer’s disease, Elayta was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Elayta is covered by composition of matter patents world wide.
Elayta is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer’s disease. More information about these studies may be found here.
Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century
Cognition Therapeutics is a member of the Biotechnology Innovation Organization (BIO), which is dedicated to promoting the value of the current and future biopharmaceutical industry. Modern biotechnology may be a young industry, but in just a few decades the entrepreneurs, scientists, researchers and investors working in this field will have established themselves at the forefront of medical innovation. To learn more about how their work may transform the way we treat patients with a wide range of once-devastating diseases, such as Alzheimer’s disease, and what tools, resources and policies will pave the way to these advances, please click here.